Phase I study of oral suberoylanilide hydroxamic acid (SAHA) in patients (pts) with advanced leukemias or myelodysplastic syndromes (MDS).

被引：0
|
作者：
Garcia-Manero, G
Canalli, AA
Wierda, W
Cortes, J
O'Brien, S
Cupo, A
Secrist, JP
Davis, J
Faderl, S
Giles, F
Chiao, JH
Richon, V
Issa, JP
Kantarjian, H
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Aton Pharma, Tarrytown, NY USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4742
引用
收藏
页码：254B / 254B
页数：1
相关论文
共 50 条
  • [41] Preliminary results from a phase I study of Revlimid® (Lenalidomide) in combination with Vidaza® (Azacitidine) in patients with advanced myelodysplastic syndromes (MDS)
    Sekeres, Mikkael A.
    List, Alan
    Cuthbertson, David
    Paquette, Ronald
    Loughran, Thomas
    Maciejewski, Jaroslaw P.
    BLOOD, 2007, 110 (11) : 437A - 437A
  • [42] A phase I trial of ipilimumab (ipi) in patients (pts) with myelodysplastic syndromes (MDS) after hypomethylating agent (HMAs) failure.
    Zeidan, Amer M.
    Knaus, Hanna
    Robinson, Tara M.
    Zeidner, Joshua F.
    Blackford, Amanda L.
    Rizzieri, David
    Frattini, Mark G.
    Levy, Moshe Yair
    Schroeder, Mark A.
    Ferguson, Anna K.
    Sheldon, Katherine
    Dezern, Amy Elizabeth
    Gojo, Ivana
    Gore, Steven
    Streicher, Howard
    Luznik, Leo
    Duffield, Amy
    Smith, B. Douglas
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed diffuse large B-cell lymphoma (DLBCL)
    Crump, M.
    Coiffier, B.
    Jacobsen, E. D.
    Sun, L.
    Ricker, J. L.
    Xie, H.
    Frankel, S. R.
    Randolph, S. S.
    Cheson, B. D.
    EJC SUPPLEMENTS, 2007, 5 (04): : 346 - 346
  • [44] Characteristics and Outcomes of Younger Adult Patients (Pts) with Myelodysplastic Syndromes (MDS): A Multicenter Retrospective Study
    Abaza, Yasmin
    Xie, Zhuoer
    Burkart, Madelyn
    Badar, Talha
    Desai, Pinkal
    Shallis, Rory M.
    Patel, Anand Ashwin
    Cohen-Nowak, Adam
    Oh, Timothy S.
    Walker, Chelsea
    Easwar, Neela
    Kewan, Tariq
    Cannova, Joseph
    Bell-Burdett, Kirsten
    Al Ali, Najla H.
    Sallman, David A.
    Roboz, Gail J.
    Carraway, Hetty E.
    Zeidan, Amer M.
    Patnaik, Mrinal M.
    Altman, Jessica K.
    Komrokji, Rami S.
    BLOOD, 2023, 142
  • [45] A phase 2/3 trial of oral azacitidine (Oral-AZA) in patients (pts) with low- or intermediate-risk myelodysplastic syndromes (MDS)
    Garcia-Manero, Guillermo
    Santini, Valeria
    Fenaux, Pierre
    Suzuki, Takahiro
    Sekeres, Mikkael A.
    He, Jun
    Barkalifa, Ronit
    Vigil, Carlos Enrique
    Prebet, Thomas
    Komrokji, Rami S.
    Giagounidis, Aristoteles
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] PHASE 1 STUDY OF SORAFENIB IN PATIENTS WITH REFRACTORY ACUTE LEUKEMIAS AND MYELODYSPLASTIC SYNDROMES
    Al-Kali, A.
    Borthakur, G.
    Kantarjian, H.
    Ravandi, F.
    Zhang, W.
    Konopleva, M.
    Wright, J.
    Faderl, S.
    Verstovsek, S.
    Mathews, S.
    Andreef, M.
    Cortes, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 25 - 25
  • [47] Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Hearn, Katherine P.
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney D.
    Konopleva, Marina
    Borthakur, Gautam
    Fenaux, Pierre
    Petrone, Michael E.
    Zbyszewski, Patrick Simon
    Fruchtman, Steven M.
    Silverman, Lewis R.
    BLOOD, 2016, 128 (22)
  • [48] Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) unresponsive to conventional therapy.
    Duvic, M
    Talpur, R
    Zhang, C
    Goy, A
    Richon, V
    Frankel, SR
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 577S - 577S
  • [49] Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes
    Komrokji, Rami S.
    Raza, Azra
    Lancet, Jeffrey E.
    Ren, Chen
    Taft, David
    Maniar, Manoj
    Wilhelm, Francois
    List, Alan F.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (04) : 517 - 524
  • [50] Trisenox® (arsenic trioxide, ATO) in patients (pts) with myelodysplastic syndromes (MDS):: Preliminary findings in a phase II clinical study.
    List, AF
    Schiller, GJ
    Mason, J
    Douer, D
    Paradise, C
    BLOOD, 2002, 100 (11) : 790A - 790A
12345